Drug Trial Radar · NCT01174823
Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients
Last checked: Nov 20, 2026Latest source record: Sep 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
245
Actual
Start
Jun 2010
Primary completion
Oct 2010
Study completion Dec 2010
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Aug 4, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to study the safety and efficacy of bepotastine besilate ophthalmic solution in allergic conjunctivitis patients.
Conditions
- Allergic Conjunctivitis
Interventions
bepotastine besilate ophthalmic solutionDrug
sterile ophthalmic solution
placebo comparator ophthalmic solutionDrug
sterile ophthalmic solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) - Mean Change in Total ScoreTime frame: Baseline, 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ISTA Pharmaceuticals, Inc.
Irvine, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.